Abstract
A high percentage of endometrial carcinomas contain oestrogen and progesterone receptors. For endocrine therapy of recurrent endometrial carcinoma, only high-dose progestins are in clinical use. As, therefore, the development of new endocrine treatment strategies is of great interest, suitable animal models for this tumour are essential. Up to now, only human tumour xenografts transplanted in immune-deficient nude mice, but no syngeneic in vivo tumour models, have been available. In the present article we describe the hormone sensitivity of the EnDA endometrial adenocarcinoma of the DA/Han rat growing as s.c. implants in DA/Han rats and athymic nude mice in serial passage. In both species, the tumour expresses oestrogen, but no progesterone receptors. Transplanted in DA/Han rats or nude mice, ovariectomy reduced tumour weight by 64% and 46% respectively. In both species substitution of ovariectomized animals with oestradiol restored tumour weights to intact control levels. Oestradiol substitution of intact animals did not further enhance tumour growth. The growth of the primary tumour was inhibited by medroxyprogesterone acetate (MPA) at a dose of 100 mg/kg by 67% and by tamoxifen at a dose of 20 mg/kg by 38%. Lung metastases were regularly seen in both species, although to a lesser extent in nude mice than in DA/Han rats. Tamoxifen treatment did not alter the number of lung metastases, whereas MPA or ovariectomy produced a significant reduction in the number of lung metastases. The EnDA endometrial carcinoma of the DA/Han rat with respect to its oestrogen sensitivity, oestrogen receptor expression, morphology and metastatic growth, grossly resembles a typical endometrial adenocarcinoma and can therefore be regarded as auseful in vivo experimental model for the evaluation of new endocrine treatment strategies.
Similar content being viewed by others
Abbreviations
- MPA:
-
medroxyprogesterone acetate
- E2 :
-
oestradiol undecylate
References
Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE (1990) Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol 95: 247–254
Cramer DW, Knapp RC (1979) Review of epidemiologic studies of endometrial cancer and exogenous estrogen. Obstet Gynecol 45: 521–526
Cramer DW, Cutler SJ, Christine B (1974) Trends in the incidence of endometrial cancer in the United States. Gynecol Oncol 2: 130–143
Deerberg F, Rehm S, Rapp KG (1985) Survival data and age-associated spontaneous diseases of two strains of rats. In: Archibal J, Ditchfield J, Rowsell HC (eds) The contribution of laboratory animal science to the welfare of man and animals. Fischer, Stuttgart New York pp 171–179
EORTC Breast Cancer Cooperative Group (1973) Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9: 379–381
Giavazzi R (1991) Metastatic models. In Boven e, Winograd B (eds) The nude mouse in oncology research. CRC Press Boca Raton pp 118–132
Goodman DG, Ward JM, Squire RA, Chu KC, Linhart MS (1979) Neoplastic and non-neoplastic lesions in aging F344 rats. Appl Pharmacol 48: 237–248
Gorodecki J, Mortel R, Ladda RL, Ward SP, Geder L, Rapp F (1979) Establishment and characterization of a new endometrial cancer cell line (SCRC-1). Am J Obstet Gynecol 135: 671–679
Gottardis MM, Ertürk E, Rose DP (1983) Effects of progesterone administration ofN-nitrosomethylurea-induced rat mammary carcinogenesis. Eur J Cancer Clin Oncol 19: 1479–1484
Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC (1990) Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated endometrial carcinoma (EnCa 101) in athymic mice. Cancer Res 50: 3189–3192
Grenman SE, Dyke DL van, Worsham MJ, Rosario F del, Roberts RJ, McClatchey KD, Schwartz DR, Ramesh BaBu V, Carey TE (1988) UM-EC-1 a new hyperploid human cell line derived from a poorly differentiated endometrial cancer. Cancer Res 48: 1864–1873
Grosso DS, Surwit EA, Davis JR, Christian CD (1984) Hormonal receptors in endometrial cancer. Prog Cancer Res Ther 31: 367–375
Higman B, Greenman DL, Norvell MJ, Farmer J, Shellenberger TE (1980) Neoplastic and preneoplastic lesions induced in female C3H mice by diets containing diethylstibestrol or 17ß-estradiol. J Environ Pathol Toxicol 4: 81–95
Horvath G, Stendahl U, Kalling M, Fernö M, Himmelmann A, Hajba A (1990) Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri—a Phase II study of toremifene. Anticancer Res 10: 323–326
Jordan VC, Gottardis MM, Robinson SP, Friedl A (1989) Immune-deficient animals to study “hormone dependent” breast and endometrial cancer. J Steroid Biochem 34: 169–176
Leclerq G (1987) Technical pitfalls, methodological improvements and quality control of steroid hormone receptors assays. Eur J Cancer Clin Oncol 23: 453–458
Meissner WA, Sommers SC, Sherman G (1957) Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen. Cancer 10: 500–509
Nagaoka T, Onodera H, Matsushima Y, Todate A, Shibutani M, Ogasawara H, Maekawa A (1982) Spontaneous uterine adenocarcinoma in aged rats and their relation to endocrine imbalance. J Cancer Res Clin Oncol 116: 623–628
Neumann F, Elger W, Nishno Y, Steinbeck H (1977) Probleme der Dosisfindung: Sexualhormone. Drug Res 27: 296–318
Newbold RR, Bullock BC, McLachlan JA (1990) Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. Cancer Res 50: 7677–7681
Nishida M, Kasahara K, Kaneko M, Iwasaki H (1985) Establishment of a new endometrial adenocarcinoma cell line Ishikawa cells, containing estrogen and progesterone receptors. Acta Obst Gynecol Jpn 37: 1103–1111
Niwa K, Tanaka T, Mori H, Yokoyama Y, Furui T, Mori H, Tamaya T (1991) Rapid induction of endometrial carcinoma in ICR mice treated withN-methyl-N-nitrosourea and 17β-estradiol. Jpn J Cancer Res 82: 1391–1396
Ogino H, Fujimoto M, Oshiro H, matsumoto K, Funahashi M, Kaneko C, Hirono I (1989) Experimental induction of uterine cancer in rats byN-ethyl-N'-nitro-N-nitrosoguanidine dissolved in polyethylene glycol. Pathol Res Pract 185: 214–217
Satyaswaroop PG, Zaino R, Clarke CL, Mortel R (1987) Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma. J Steroid Biochem 27: 431–438
Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672
Schulz KD, Schmidt-Rhode P, Zippel HH, Sturm G (1986) New concepts of adjuvant drug treatment in endometrial cancer. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds) Endometrial cancer. Zuckschwerdt, München, pp 169–180
Schulz KD, Zippel HH, Rück A, Hölzel F (1988) Selection and practicability of different hormonal treatment methods in endometrial cancer. Prog Cancer Res Ther 35: 445–451
Seen HJ, Drings P, Glaus A, Jungi WF, Sauer R, Schlag P (1992) Checkliste Onkologie. In: Sturm A, Largiadèr F, Wicki O (eds) Checkliste der aktuellen Medizin. Thieme, Stuttgart New York pp 151–155
Silverberg SG (1984) New aspects of endometrial carcinoma. Clin Obstet Gynecol 11: 189–208
Taki I, Iijima H (1963) A new method of producing endometrial cancer in mice. Am J Obstet Gynecol 87: 926–934
Tanaka T, Mori H (1983) Experimental induction of uterine cancer in rats byN-methyl-N'-nitro-N-nitrosoguanidine. Pathol Res Pract 178: 20–26
Taylor RW (1987) Future aspects of endometrial cancer: a summary of the round table discussion. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds) Endometrial cancer. Zuckschwerdt, München, pp 200–201
Verdeal K, Ertürk E, Rose DP (1986) Endometrial adenomatous hyperplasia and adenocarcinoma, and multiple endocrinopathies in rats exposed toN-nitrosomethylurea. Anticancer Res 6: 5–10
Young P, Ehrlich C, Cleary R (1976) Progesterone binding ovarian and endometrial carcinomas. Am J Obstet Gynecol 125: 353–360
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Horn, D.W., Vollmer, G., Deerberg, F. et al. The EnDA endometrial adenocarcinoma: an oestrogen-sensitive, metastasizing, in vivo tumour model of the rat. J Cancer Res Clin Oncol 119, 450–456 (1993). https://doi.org/10.1007/BF01215924
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01215924